CN108245699A - 可调节透明度的创面敷料的制备方法 - Google Patents
可调节透明度的创面敷料的制备方法 Download PDFInfo
- Publication number
- CN108245699A CN108245699A CN201611250022.9A CN201611250022A CN108245699A CN 108245699 A CN108245699 A CN 108245699A CN 201611250022 A CN201611250022 A CN 201611250022A CN 108245699 A CN108245699 A CN 108245699A
- Authority
- CN
- China
- Prior art keywords
- water
- soluble
- wound dressing
- pva
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 76
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims abstract description 72
- 239000004814 polyurethane Substances 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 35
- 239000007864 aqueous solution Substances 0.000 claims abstract description 24
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 23
- 239000011259 mixed solution Substances 0.000 claims description 22
- 238000010257 thawing Methods 0.000 claims description 20
- 230000008014 freezing Effects 0.000 claims description 19
- 238000007710 freezing Methods 0.000 claims description 19
- 239000003242 anti bacterial agent Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 14
- 230000000845 anti-microbial effect Effects 0.000 claims description 12
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000001746 injection moulding Methods 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 3
- 240000003291 Armoracia rusticana Species 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000004368 Modified starch Substances 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 229920000141 poly(maleic anhydride) Polymers 0.000 claims description 3
- 239000004584 polyacrylic acid Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 150000003557 thiazoles Chemical class 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000002085 enols Chemical class 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 abstract description 6
- 206010052428 Wound Diseases 0.000 description 50
- 208000027418 Wounds and injury Diseases 0.000 description 50
- 239000006185 dispersion Substances 0.000 description 7
- 238000002834 transmittance Methods 0.000 description 5
- 230000035876 healing Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 2
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供一种可调节透明度的创面敷料的制备方法,包括将水溶性聚乙烯醇(PVA)水溶液和水溶性聚氨酯(PU)水溶液按照一定的比例混合均匀,并通过重复多次冷冻和解冻并浸泡,并于恒温恒湿箱中处理。在制备过程中,通过调节PVA与PU的质量比,控制所述创面敷料的透明度,也可以选择性加入调节理化性能的辅料或抗菌剂。在制备和使用所述创面敷料的过程中,当所述水的含量减少,所述创面敷料的透明度增大,当所述水的含量增加,所述创面敷料的透明度减小。从而有利于对创面敷料的透明度有不同要求的创面进行观察和护理。
Description
技术领域
本发明属于生物医用材料领域。更确切地说,本发明涉及一种可调节透明度的创面敷料的制备方法。
技术背景
医用敷料的临床应用主要集中在手术后伤口护理、烧伤、外部创伤和长期不愈性溃疡等,尤其是应用于创面的敷料,其市场前景广阔。2012年世界创伤敷料市场的规模为117亿美元,2017年,全球高端医用敷料销售收入预计将达到160亿美元,2021年将达到185亿美元。
据临床经验,创面愈合过程中,创面的颜色与炎症反应和创面的愈合状态存在着显著的关系。健康血流的肉芽组织或处于增生期的创面,呈红色;当出现坏死残留物、伤口基底附有黄色分泌物和脱落坏死组织,如果呈黄色表明已感染;当创面缺乏血液供应而坏死并有干痂时,呈黑色。因此,伤口的颜色提供了创面状态的重要线索,据此可以评估创面是否感染、感染情况、愈合情况等。传统不透明的创面敷料,为观察创面状态需要撤包并更换,一则造成伤口暴露于外界环境中,易引发创面感染,二则当组织与敷料粘连时进行分离,易引发伤口的再次损伤,干扰创面的愈合进程。因此,一种创面敷料吸液后保湿的同时具有一定的透明度,对临床治疗创面,尤其是慢性创面,极具临床应用价值。保湿可以让创面保持湿润的愈合环境,透明可以让医生直观诊断出创面的情况,如有必要可采取早期的感染预防措施,极大的减少严重感染的发生。
发明内容
有鉴于如此,提供一种可调节透明度的创面敷料的制备方法。
一种可调节透明度的创面敷料的制备方法,包括以下步骤:将水溶性聚乙烯醇(PVA)和水溶性聚氨酯(PU)分别溶于水中,以制备质量分数为0.5-10%的水溶性聚乙烯醇(PVA)水溶液和质量分数为0.1-10%的水溶性聚氨酯(PU)水溶液;
将所述水溶性聚乙烯醇(PVA)水溶液和所述水溶性聚氨酯(PU)水溶液按照水溶性聚乙烯醇(PVA)和水溶性聚氨酯(PU)的质量比混合均匀,所述质量比为(30-99.9):(0.01-70),通过调节所述质量比,控制所述创面敷料的透明度。
将所述混合溶液注模,静置后冷冻,取出,然后解冻,重复所述冷冻和解冻的过程,然后将经过所述冷冻和解冻的过程的混合物于水中反复浸泡并换水,再置于恒温恒湿箱中处理,获得所述创面敷料。
进一步地,所述创面敷料保存于2-8度、50%以上湿度的环境中。
进一步地,所述冷冻过程是将所述混合溶液置于零下20℃至零下80℃的温度下冷冻4-72小时,所述解冻的时间为2-8小时,所述冷冻和解冻的过程重复2-6次,所述置于恒温恒湿箱中处理的时间为0.5-24小时。
进一步地,还包括制备辅料溶液并将所述辅料溶液加入到所述混合溶液中,所述辅料溶液的质量分数为0.01-20%。
进一步地,所述辅料溶液包括一种或多种辅料,所述辅料包括水溶性合成高分子材料和水溶性天然高分子材料,所述水溶性合成高分子材料包括聚丙烯酰胺、聚丙烯酸、聚乙烯吡咯烷酮、聚马来酸酐、聚季胺盐、聚乙二醇、改性纤维素和改性淀粉;所述水溶性天然高分子材料包括胶原、明胶、壳聚糖和透明质酸。
进一步地,所述混合溶液中所述水溶性聚乙烯醇(PVA)、所述水溶性聚氨酯(PU)和所述辅料的质量比为(30-99.9):(0.01-70):(0-20)。
进一步地,还包括制备抗菌剂溶液或抗菌剂分散液并将所述抗菌剂溶液或抗菌剂分散液加入到所述混合溶液中,所述抗菌剂溶液的质量分数为0.01-20%,所述抗菌剂分散液的固含量为0.01-20%。
进一步地,所述抗菌剂溶液或所述抗菌剂分散液包括一种或多种抗菌剂,所述抗菌剂包括无机抗菌剂、有机抗菌剂和天然抗菌剂。
进一步地,所述无机抗菌剂包括银、锌、氧化锌和磷酸二氢铵;所述有机抗菌剂包括酰基苯胺类、咪唑类、噻唑类和季铵盐类;所述天然抗菌剂包括甲壳素和山葵。
进一步地,所述混合溶液中所述水溶性聚乙烯醇(PVA)、所述水溶性聚氨酯(PU)和所述抗菌剂的质量比为(30-99.9):(0.01-70):(0-5)。
一种应用上述方法制备的可调节透明度的创面敷料,包括水溶性聚乙烯醇(PVA)、水溶性聚氨酯(PU)和水,所述水溶性聚乙烯醇(PVA)和所述水溶性聚氨酯(PU)的质量比为(30-99.9):(0.01-70),所述水的含量在所述水溶性聚乙烯醇(PVA)和所述水溶性聚氨酯(PU)的最大吸水量的范围内,当所述水的含量减少,所述创面敷料的透明度增大,当所述水的含量增加,所述创面敷料的透明度减小。
与现有技术相比,本发明通过将水溶性聚乙烯醇(PVA)水溶液和水溶性聚氨酯(PU)水溶液按照一定比例的混合,并且通过重复多次冷冻和解冻并浸泡,从而得到不同透明度的创面敷料,并且该创面敷料在使用过程中,随着该创面敷料中的水的含量的变化,其透明度会发生变化,有利于对创面敷料的透明度有不同要求的创面进行观察和护理。
附图说明
图1为可调节透明度的创面敷料的制备方法流程图。
如下具体实施方式将结合上述附图进一步说明本发明。
具体实施方式
以下以具体实施例来说明本发明的技术方案,但本发明的保护范围不限于此:
在本发明的实施例中,如图1所示,一种可调节透明度的创面敷料的制备方法,包括以下步骤:
S101:将水溶性聚乙烯醇(Polyvinyl alcohol,PVA)和水溶性聚氨酯(Polyurethane,PU)分别溶于水中,以制备质量分数为0.5-10%的水溶性聚乙烯醇(PVA)水溶液和质量分数为0.1-10%的水溶性聚氨酯(PU)水溶液;
S102:将所述水溶性聚乙烯醇(PVA)水溶液和所述水溶性聚氨酯(PU)水溶液按照水溶性聚乙烯醇(PVA)和水溶性聚氨酯(PU)的质量比混合均匀,所述质量比为(30-99.9):(0.01-70),通过调节所述质量比,控制所述创面敷料的透明度;
S103:将所述混合溶液注模,静置后冷冻,取出,然后解冻,重复所述冷冻和解冻的过程,然后将经过所述冷冻和解冻的过程的混合物于水中反复浸泡并换水,再置于恒温恒湿箱中处理,获得所述创面敷料。
在本实施例中,所述创面敷料保存于2-8度、50%以上湿度的环境中。
在本实施例中,所述创面敷料中水溶性聚乙烯醇(PVA)的质量分数为30-99.9%,所述水溶性聚氨酯(PU)的质量分数为0.01-70%。
在本实施例中,所述冷冻过程是将所述混合溶液置于零下20℃至零下80℃的温度下冷冻4-72小时,所述解冻的时间为2-8小时,所述冷冻和解冻的过程重复2-6次,所述置于恒温恒湿箱中处理的时间为0.5-24小时。
在一实施例中,所述敷料的制备方法,还包括制备辅料溶液并将所述敷料溶液加入到所述混合溶液中,所述辅料溶液包括一种或多种辅料,所述辅料包括水溶性合成高分子材料和水溶性天然高分子材料。所述水溶性合成高分子材料包括聚丙烯酰胺、聚丙烯酸、聚乙烯吡咯烷酮、聚马来酸酐、聚季胺盐、聚乙二醇、改性纤维素、改性淀粉;所述水溶性天然高分子材料包括胶原、明胶、壳聚糖、透明质酸。所述敷料中所述辅料的质量分数为0-20%。在本实施例中,所述混合溶液中所述水溶性聚乙烯醇(PVA)、所述水溶性聚氨酯(PU)和所述辅料的质量比为(30-99.9):(0.01-70):(0-20)。
在另一实施例中,所述敷料的制备方法,还包括制备抗菌剂溶液或分散液并将所述抗菌剂溶液或分散液加入到所述混合溶液中,所述抗菌剂溶液或分散液包括一种或多种抗菌剂,所述抗菌剂包括无机抗菌剂、有机抗菌剂和天然抗菌剂。所述无机抗菌剂包括银、锌、氧化锌和磷酸二氢铵;所述有机抗菌剂包括酰基苯胺类、咪唑类、噻唑类和季铵盐类;所述天然抗菌剂包括甲壳素和山葵。所述敷料中所述抗菌剂的质量分数为0-5%。在本实施例中,所述混合溶液中所述水溶性聚乙烯醇(PVA)、所述水溶性聚氨酯(PU)和所述抗菌剂的质量比为(30-99.9):(0.01-70):(0-5)。
在本发明的实施例中,还提供一种应用上述的方法制备的可调节透明度的创面敷料,包括水溶性聚乙烯醇(PVA)、水溶性聚氨酯(PU)和水,所述水溶性聚乙烯醇(PVA)和所述水溶性聚氨酯(PU)的质量比为(30-99.9):(0.01-70),所述水的含量在所述水溶性聚乙烯醇(PVA)和所述水溶性聚氨酯(PU)的最大吸水量的范围内,当所述水的含量减少,所述创面敷料的透明度增大,当所述水的含量增加,所述创面敷料的透明度减小。
实施例1
制备质量分数0.5%的水溶性聚乙烯醇(PVA)水溶液(A液)和质量分数10%水溶性聚氨酯(PU)水溶液(B液);制备质量分数1%的聚丙烯酰胺水溶液(C液);制备2%质量分数的银离子分散液(D液);将A液、B液、C液和D液按溶质质量比例A:B:C:D=30:68:1:1,即水溶性聚乙烯醇(PVA)的质量分数为30%,水溶性聚氨酯(PU)的质量分数为68%,聚丙烯酰胺的质量分数为1%、银的质量分数为1%,混合均匀;将上述混合溶液注模,静置后置于零下20℃的温度下冷冻72小时,取出,于室温下解冻8小时,所述冷冻和解冻的过程重复6次,然后将经过所述冷冻和解冻的过程的混合物于纯净水中反复浸泡并换水,再置于恒温恒湿箱中处理0.5-4小时,获得所述创面敷料。将所制备敷料保存于4度、50%湿度的环境中。在本实施例中,测得的敷料含水率为8.0±1.2%,透光率为3.2±1.1%。
实施例2
制备质量分数10%的水溶性聚乙烯醇(PVA)水溶液(A液)和质量分数0.1%水溶性聚氨酯(PU)水溶液(B液);制备质量分数2%的聚乙二醇水溶液(C液);制备0.5%质量分数的季铵盐分散液(D液);将A液、B液、C液和D液按溶质质量比例A:B:C:D=98:1:0.5:0.5,即水溶性聚乙烯醇(PVA)的质量分数为98%,水溶性聚氨酯(PU)的质量分数为1%,聚乙二醇的质量分数为0.5%、季铵盐的质量分数为1%,混合均匀;将上述混合溶液注模,静置后置于零下80℃的温度下冷冻4小时,取出,于室温下解冻2小时,所述冷冻和解冻的过程重复3次,然后将经过所述冷冻和解冻的过程的混合物于纯净水中反复浸泡并换水,再置于恒温恒湿箱中处理0.5小时,获得所述创面敷料。将所制备敷料保存于4度、50%湿度的环境中。在本实施例中,测得的敷料含水量为72.2±0.2%时,透光率为0%;当其含水率为38.2±0.2%时,透光率为4.9±0.1%;当其含水率为11.1±0.5%时,透光率为33.9±1.7%。
实施例3
制备质量分数5%的水溶性聚乙烯醇(PVA)水溶液(A液)和质量分数5%水溶性聚氨酯(PU)水溶液(B液);将A液和B液按溶质质量比例A:B=70:30,即水溶性聚乙烯醇(PVA)的质量分数为70%,水溶性聚氨酯(PU)的质量分数为30%,混合均匀;将上述混合溶液注模,静置后置于零下60℃的温度下冷冻6小时,取出,于室温下解冻4小时,所述冷冻和解冻的过程重复3次,然后将经过所述冷冻和解冻的过程的混合物于纯净水中反复浸泡并换水,再置于恒温恒湿箱中处理1小时,获得所述创面敷料。将所制备敷料保存于4度、50%湿度的环境中。在本实施例中,测得的敷料含水量为9.6±0.3%时,透光率为34.5±0.3%。
实施例4
制备质量分数8%的水溶性聚乙烯醇(PVA)水溶液(A液)和质量分数8%水溶性聚氨酯(PU)水溶液(B液);制备质量分数2%的聚乙烯吡咯烷酮水溶液(C液);将A液、B液、C液和D液按溶质质量比例A:B:C=95:0.01:4.94,即水溶性聚乙烯醇(PVA)的质量分数为95%,水溶性聚氨酯(PU)的质量分数为0.01%,聚乙烯吡咯烷酮的质量分数为4.94%,混合均匀;将上述混合溶液注模,静置后置于零下40℃的温度下冷冻10小时,取出,于室温下解冻3小时,所述冷冻和解冻的过程重复6次,然后将经过所述冷冻和解冻的过程的混合物于纯净水中反复浸泡并换水,再置于恒温恒湿箱中处理2小时,获得所述创面敷料。将所制备敷料保存于4度、50%湿度的环境中。在本实施例中,测得的敷料含水率为11.8±0.5%时,其透光率为10.9±0.1%。
Claims (10)
1.一种可调节透明度的创面敷料的制备方法,包括以下步骤:
将水溶性聚乙烯醇(PVA)和水溶性聚氨酯(PU)分别溶于水中,以制备质量分数为0.5-10%的水溶性聚乙烯醇(PVA)水溶液和质量分数为0.1-10%的水溶性聚氨酯(PU)水溶液;
将所述水溶性聚乙烯醇(PVA)水溶液和所述水溶性聚氨酯(PU)水溶液按照水溶性聚乙烯醇(PVA)和水溶性聚氨酯(PU)的质量比混合均匀,所述质量比为(30-99.9):(0.01-70),通过调节所述质量比,控制所述创面敷料的透明度;
将所述混合溶液注模,静置后冷冻,取出,然后解冻,重复所述冷冻和解冻的过程,然后将经过所述冷冻和解冻的过程的混合物于水中反复浸泡并换水,再置于恒温恒湿箱中处理,获得所述创面敷料。
2.如权利要求1所述的制备方法,其特征在于,所述冷冻过程是将所述混合溶液置于零下20℃至零下80℃的温度下冷冻4-72小时,所述解冻的时间为2-8小时,所述冷冻和解冻的过程重复2-6次,所述置于恒温恒湿箱中处理的时间为0.5-24小时。
3.如权利要求1所述的制备方法,其特征在于,还包括制备辅料溶液并将所述辅料溶液加入到所述混合溶液中,所述辅料溶液的质量分数为0.01-20%。
4.如权利要求3所述的制备方法,其特征在于,所述辅料溶液包括一种或多种辅料,所述辅料包括水溶性合成高分子材料和水溶性天然高分子材料,所述水溶性合成高分子材料包括聚丙烯酰胺、聚丙烯酸、聚乙烯吡咯烷酮、聚马来酸酐、聚季胺盐、聚乙二醇、改性纤维素和改性淀粉;所述水溶性天然高分子材料包括胶原、明胶、壳聚糖和透明质酸。
5.如权利要求4所述的制备方法,其特征在于,所述混合溶液中所述水溶性聚乙烯醇(PVA)、所述水溶性聚氨酯(PU)和所述辅料的质量比为(30-99.9):(0.01-70):(0-20)。
6.如权利要求1所述的制备方法,其特征在于,还包括制备抗菌剂溶液或抗菌剂分散液并将所述抗菌剂溶液或抗菌剂分散液加入到所述混合溶液中,所述抗菌剂溶液的质量分数为0.01-20%,所述抗菌剂分散液的固含量为0.01-20%。
7.如权利要求6所述的制备方法,其特征在于,所述抗菌剂溶液或所述抗菌剂分散液包括一种或多种抗菌剂,所述抗菌剂包括无机抗菌剂、有机抗菌剂和天然抗菌剂。
8.如权利要求7所述的制备方法,其特征在于,所述无机抗菌剂包括银、锌、氧化锌和磷酸二氢铵;所述有机抗菌剂包括酰基苯胺类、咪唑类、噻唑类和季铵盐类;所述天然抗菌剂包括甲壳素和山葵。
9.如权利要求8所述的制备方法,其特征在于,所述混合溶液中所述水溶性聚乙烯醇(PVA)、所述水溶性聚氨酯(PU)和所述抗菌剂的质量比为(30-99.9):(0.01-70):(0-5)。
10.一种应用如权利要求1所述的方法制备的可调节透明度的创面敷料,其特征在于,所述创面敷料包括水溶性聚乙烯醇(PVA)、水溶性聚氨酯(PU)和水,所述水溶性聚乙烯醇(PVA)和所述水溶性聚氨酯(PU)的质量比为(30-99.9):(0.01-70),所述水的含量在所述水溶性聚乙烯醇(PVA)和所述水溶性聚氨酯(PU)的最大吸水量的范围内,当所述水的含量减少,所述创面敷料的透明度增大,当所述水的含量增加,所述创面敷料的透明度减小。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611250022.9A CN108245699B (zh) | 2016-12-29 | 2016-12-29 | 可调节透明度的创面敷料的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611250022.9A CN108245699B (zh) | 2016-12-29 | 2016-12-29 | 可调节透明度的创面敷料的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108245699A true CN108245699A (zh) | 2018-07-06 |
CN108245699B CN108245699B (zh) | 2021-06-11 |
Family
ID=62720763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611250022.9A Active CN108245699B (zh) | 2016-12-29 | 2016-12-29 | 可调节透明度的创面敷料的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108245699B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108950842A (zh) * | 2018-10-17 | 2018-12-07 | 南通薇星纺织科技有限公司 | 吸湿排汗抗菌面料及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1438943A1 (de) * | 2003-01-20 | 2004-07-21 | Beiersdorf AG | Verfahren zur Herstellung von Pflastern |
CN1562382A (zh) * | 2003-08-29 | 2005-01-12 | 杭州拜康医用产品有限公司 | 含有聚氨酯水乳液的水凝胶型创伤敷料及其制备方法 |
WO2013089434A1 (ko) * | 2011-12-12 | 2013-06-20 | 테고사이언스(주) | 상처 치유용 드레싱재 |
CN103520767A (zh) * | 2013-10-28 | 2014-01-22 | 山东赛克赛斯药业科技有限公司 | 一种抗菌促愈水凝胶敷料及其制备方法 |
CN104826156A (zh) * | 2015-04-02 | 2015-08-12 | 蚌埠市惠鸿电子科技有限公司 | 一种液体创可贴的制备配方 |
CN105497960A (zh) * | 2015-12-28 | 2016-04-20 | 王书美 | 一种具有促进伤口愈合功效的医用敷料及制法 |
-
2016
- 2016-12-29 CN CN201611250022.9A patent/CN108245699B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1438943A1 (de) * | 2003-01-20 | 2004-07-21 | Beiersdorf AG | Verfahren zur Herstellung von Pflastern |
CN1562382A (zh) * | 2003-08-29 | 2005-01-12 | 杭州拜康医用产品有限公司 | 含有聚氨酯水乳液的水凝胶型创伤敷料及其制备方法 |
WO2013089434A1 (ko) * | 2011-12-12 | 2013-06-20 | 테고사이언스(주) | 상처 치유용 드레싱재 |
CN103520767A (zh) * | 2013-10-28 | 2014-01-22 | 山东赛克赛斯药业科技有限公司 | 一种抗菌促愈水凝胶敷料及其制备方法 |
CN104826156A (zh) * | 2015-04-02 | 2015-08-12 | 蚌埠市惠鸿电子科技有限公司 | 一种液体创可贴的制备配方 |
CN105497960A (zh) * | 2015-12-28 | 2016-04-20 | 王书美 | 一种具有促进伤口愈合功效的医用敷料及制法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108950842A (zh) * | 2018-10-17 | 2018-12-07 | 南通薇星纺织科技有限公司 | 吸湿排汗抗菌面料及其制备方法 |
CN108950842B (zh) * | 2018-10-17 | 2021-02-23 | 广东国色婚纱礼服有限公司 | 吸湿排汗抗菌面料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108245699B (zh) | 2021-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Obagi et al. | Principles of wound dressings: a review | |
Stoica et al. | Nanomaterials for wound dressings: an up-to-date overview | |
Abdelrahman et al. | Wound dressings: principles and practice | |
Yuan et al. | ZIF nano-dagger coated gauze for antibiotic-free wound dressing | |
Tarusha et al. | Alginate membranes loaded with hyaluronic acid and silver nanoparticles to foster tissue healing and to control bacterial contamination of non-healing wounds | |
Mirani et al. | Smart dual‐sensor wound dressing for monitoring cutaneous wounds | |
CN100427149C (zh) | 纳米银生物仿生敷料的制备方法 | |
US20120316129A1 (en) | Liquid dressing containing chitosan derivative and preparation method thereof | |
CN101954117A (zh) | 止血抑菌生物敷料及其制备方法 | |
CN103961738A (zh) | 一种壳聚糖-纳米银伤口敷料及其制备方法 | |
CN104622645A (zh) | 负压吸附医用敷料及使用该医用敷料愈合创面的方法 | |
CN103736140A (zh) | 一种药用敷料水凝胶复合织物及其制备方法和应用 | |
Bao et al. | Antibacterial and antioxidant films based on HA/Gr/TA fabricated using electrospinning for wound healing | |
CN110859989B (zh) | 一种液体创可贴及其制备方法 | |
CN108245699A (zh) | 可调节透明度的创面敷料的制备方法 | |
CN104740141B (zh) | 一种抗菌喷剂及其制备方法 | |
Chen et al. | High-efficiency antibacterial calcium alginate/lysozyme/agnps composite sponge for wound healing | |
Liu et al. | An All‐In‐One Self‐Degradable Flexible Skin Patch with Thermostatic Control and Spontaneous Release of Antibacterial Ions to Accelerate Wound Healing | |
CN108619550A (zh) | 一种水凝胶及其制备方法 | |
CN104622643A (zh) | 负压吸附医用敷料及其应用 | |
CN110755673A (zh) | 一种羧甲基纤维素钠液体敷料及其制作方法 | |
CN108434507A (zh) | 离子介导敷料及其制备方法和应用 | |
CN113244443B (zh) | 一种水凝胶敷料及其制备方法和应用 | |
Nakamura-García et al. | Healing of Wounds Treated with Chitosan Hydrogels with Extracts from Aloe vera and Calendula officinalis | |
KR101052308B1 (ko) | 실리콘 입자를 포함하는 드레싱 재제 및 그 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |